GI CONNECT expert Prof. Gerald Prager shares an update on what HCPs must consider to achieve a long-term response in advanced colorectal cancer (CRC). Watch the video and download the accompanying slides to understand:

 

  • How to view CRC treatment as a continuum of care

  • What to consider when making treatment decisions

  • Which treatment options are available for CRC patients, 3rd line and beyond

 

After completing this programme, deepen your understanding of this topic with the interactive patient case study Long-term Management of Advanced CRC from Prof. Gerald Prager and Prof. Joleen Hubbard.

 

 

Clinical Takeaways

 

  • Treatment of advanced colorectal cancer (CRC) should be considered as a continuum of care, and patients should be offered as many life-prolonging therapies as possible

  • Decision-making at each stage of therapy should consider patients' suitability and tolerability, tumour biomarkers and prior exposure to chemotherapies and/or targeted agents

  • There are a number of treatment options for CRC patients 3rd line and beyond that should be considered, such as regorafenib, trifluridine/tipiracil as well as consideration of clinical trials and rechallenge with chemotherapy or anti-EGFR

Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).

Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Arcus, Astellas, AstraZeneca, Bayer, BMS, CECOG, Incyte, Lilly, MSD, Merck Serono, Pierre Fabre, Roche, Servier, Takeda

 

 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.  

Meet the experts Independent IME approved

Other programmes of interest

patient-support Patient Support
Oncology Endocrinology Rare diseases 
Navigating extrapulmonary neuroendocrine carcinoma (EP-NEC)

Insights for patients and care partners 

Experts
Meredith Cummins
Endorsed by
INCA
NeuroEndocrine Cancer Australia Neuroendocrine Cancer Foundation NET-Research-Foundation
Neuroendocrine Cancer UK Minkhas mission
  • clock 5 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
eks
EKS / On-demand webinar
Oncology 
ESMO 2025: Gastric and gastroesophageal cancer insights for clinical practice

On-demand materials from an Experts Knowledge Share event

Experts
Dr Elizabeth Smyth, Prof. Aziz Zaanan, Prof. Markus Moehler
Endorsed by
ESDO
Digestive Cancers Europe
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 67 MIN
  • calendar Dec 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Amgen.
podcast Video podcast
Oncology Endocrinology Rare diseases 
Understanding EP-NEC: Through diagnosis, treatment, and support

A medical oncologist and a patient advocate share their perspectives

Experts
Dr Aman Chauhan, Susan Meckler-Plummer, RN
Endorsed by
Minkhas mission Neuroendocrine Cancer UK Neuroendocrine Cancer Foundation
NET-Research-Foundation
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Nov 2025
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim 
conference-update Conference update
Oncology 
Update from AACR–NCI–EORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220C–mutant solid tumours

Clinical insights and expert discussion

Experts
Dr Alison Schram, Dr Elena Garralda
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Oct 2025

This programme has been sponsored by PMV Pharma